Survival in esophageal cancer with nonregional lymphadenopathy: a propensity score-matched analysis

J Gastrointest Surg. 2024 Jun;28(6):916-922. doi: 10.1016/j.gassur.2024.03.031. Epub 2024 Apr 2.

Abstract

Background: Survival among patients with esophageal cancer with stage IV nonregional lymphadenopathy treated with neoadjuvant therapy and surgical resection is not well described. This study aimed to compare the survival outcomes of patients with nonregional lymphadenopathy with a propensity-matched cohort of patients with locoregional disease.

Methods: This was a retrospective cohort analysis of a prospectively maintained database from a regional upper gastrointestinal cancer network in Quebec, Canada. From January 2010 to December 2022, patients with radiologically suspicious nonregional retroperitoneal or supraclavicular lymphadenopathy were identified. Using 1:1 propensity score matching, a control group without nonregional disease was created.

Results: Of the 1235 patients identified, 39 met the inclusion criteria and were allocated to the study group of whom 35 of 39 (89%) had adenocarcinoma. Retroperitoneal and supraclavicular lymphadenopathy occurred in 26 of 39 patients (67%) and 13 of 39 patients (33%). Of the 39 patients, 34 (87%) received neoadjuvant chemotherapy, and 5 (13%) received chemoradiotherapy. After resection, ypN0 of nonregional lymph node stations occurred in 21 of 39 patients (54%). When comparing the study group with a matched non-stage IV control group, the median overall survival was similar in patients with retroperitoneal lymphadenopathy (21.0 months [95% CI, 8.0-21.0] vs 27.0 months [95% CI, 13.0-41.0]; P = .262) but not with supraclavicular disease (13.0 months; 95% CI, 8.0-18.0; P = .039). The median follow-up intervals were 40.1 months (95% CI, 1.0-83.0) for the study group and 70.0 (95% CI, 33.0-106.0) for the control groups.

Conclusion: Compared with a matched cohort of patients with similar disease burden but not stage IV disease, retroperitoneal lymphadenopathy did not negatively affect survival outcomes. Multimodal curative intent therapy may be appropriate in select cases.

Keywords: Esophagus; Neoadjuvant; Nonregional.

MeSH terms

  • Adenocarcinoma* / mortality
  • Adenocarcinoma* / pathology
  • Adenocarcinoma* / therapy
  • Aged
  • Esophageal Neoplasms* / mortality
  • Esophageal Neoplasms* / pathology
  • Esophageal Neoplasms* / therapy
  • Esophagectomy
  • Female
  • Humans
  • Lymphadenopathy* / therapy
  • Male
  • Middle Aged
  • Neoadjuvant Therapy* / statistics & numerical data
  • Neoplasm Staging*
  • Propensity Score*
  • Quebec / epidemiology
  • Retrospective Studies
  • Survival Rate